SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Mast Therapeutics, Inc. (MSTX)

MSTX RSS Feed
Add MSTX Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Rhodey Red
Search This Board:
Last Post: 4/16/2015 12:49:58 PM - Followers: 313 - Board type: Free - Posts Today: 0

Mast Therapeutics
 We are a publicly traded biopharmaceutical company headquartered in San Diego, California.

We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop MST-188, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.


http://wsw.com/webcast/cowen16/MSTX/  Webcast from Cowen Healthcare Conference 03/03/14

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_07.09.2013.pdf


http://www.media-server.com/m/p/to9vgb8uhttp://www.media-server.com/m/p/to9vgb8u  Piper Jaffray Healthcare Conference 12/03/13 : 30 minute audio presentation by CEO B. Culley  NEW

http://www.masttherapeutics.com/wp-content/uploads/2012/09/MastThera_CorpPres_10.08.2013.pdf    12th Annual Bio-Investor Conference 10/08/13: 32 page PDF NEW

http://www.masttherapeutics.com/company/ceo-blog/ 
Blog Update from CEO B. Culley 12/12/13  NEW

http://www.masttherapeutics.com/investors/news/?releaseid=1887966  Data From Proof of Concept Study in Heart Failure 
01/06/13


2015 Biotech Conference Presentation Slides: January 12th 2015.  http://www.sec.gov/Archives/edgar/data/1160308/000119312515007330/d850231dex991.htm


ClinicalTrials.gov

 
A service of the U.S. National Institutes of Health

 

  • Make bi

 

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC)

This study is currently recruiting participants.
Verified July 2013 by Mast Therapeutics, Inc.
Sponsor:
Mast Therapeutics, Inc.
Information provided by (Responsible Party):
Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01737814
First received: November 27, 2012
Last updated: July 22, 2013
Last verified: July 2013

The purpose of this study is to evaluate whether ANX-188 can reduce the duration of vaso-occlusive crisis (VOC) in subjects with sickle cell disease. The study will also evaluate whether ANX-188 can reduce the frequency of rehospitalization of subjects due to a recurrence of VOC. Additionally, this study will compare the development of acute chest syndrome during VOC in subjects who receive ANX-188 to those who do not receive ANX-188.


Condition Intervention Phase
Vaso-occlusive Crisis
Sickle Cell Disease
Drug: ANX-188
Drug: Saline
Phase 3
 
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ANX-188 (Purified Poloxamer 188) Injection in Children With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Resource links provided by NLM:
 
Further study details as provided by Mast Therapeutics, Inc.:
 
Primary Outcome Measures:
  • Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease. [ Time Frame: Study participants will be followed for the duration of hospital stay, an expected average of 4 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Re-hospitalization rate for VOC [ Time Frame: Hospital discharge to 14 days post-discharge ] [ Designated as safety issue: No ]
    Occurence of acute chest syndrome [ Time Frame: Randomization to 120 hours after randomization ] [ Designated as safety issue: No ]
 
Estimated Enrollment: 388
Study Start Date: May 2013
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ANX-188
ANX-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours.
Drug: ANX-188
Placebo Comparator: Saline
Saline administered as a continuous infusion for up to 49 hours
Drug: Saline

 

 
Please refer to this study by its ClinicalTrials.gov identifier: NCT01737814

Contacts
Contact: Mast Therapeutics CT.gov Call Center 1-888-965-1238  

 
Responsible Party: Mast Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01737814     History of Changes
Other Study ID Numbers: ANX-188-01
Study First Received: November 27, 2012
Last Updated: July 22, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Mast Therapeutics, Inc.:
sickle cell disease
vaso-occlusive crisis

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on July 25, 2013

 

Technology

 

Hematology

MST-188 (lead product candidate)

MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.

 

2013 Activities

Event Timing

Initiate tQT/QTc Study Completed

Secure Orphan Designation for MST-188 for SCD in EU Completed

Activate First Site in Phase 3 Study Completed

File New Patent Applications Completed

Dose First Subject in Phase 3 Study Completed

Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met

Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA

Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14

2014 Activities

Event Timing


Present Data From Nonclinical Proof-of-Concept Study In Heart Failure  Q1 '14  Data Released 01/06/14'Showed Significant Statistical Improvement"

Initiate Phase 2 Study in ALI Q1 '14 Initiated

Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER

Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule

Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14

Request Orphan Designation for ALI in EU Q2 '14  Application Submitted

Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated

Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14

Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14

Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14

Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14

2015 Event Schedule

Initiate dosing Phase2a study in AIR001 Q1 '15.  INITIATED 2/4/15

Nonclinical Study EMBOLIC STROKE Data Q1 '15:  POSITIVE DATA RELEASED 2/11/15

Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15

Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15

EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15

Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15

Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15

EPIC STUDY COMPLETE ENROLLMENT Q4 '15

2016 EVENTS

EPIC STUDY TOP LINE DATA Q1 '16

Phase 2 Study Acute Limb Ischemia COMPLETE ENROLLMENT 2nd Half '16







 

Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug 
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be 
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.




 

Schedule 13D and 13G filings submitted since 09/30/14

  Filing Company Date of
Filing
Total Reported
Shares Owned
Shares Reported
on 13F
  Baker Bros LLC 12/31/14 4,774,434 4,774,434
SC 13G SABBY MANAGEMENT, LLC 1/21/15 11,605,388 3,539,799
SC 13G FRANKLIN RESOURCES INC 02/04/15 11,946,100 11,946,100
Reported via Event Date Name Ticker Shares * Change % of Portfolio
13F MPM Asset Management     MSTX 2,551,851    
13F Vanguard Group     MSTX 3,382,483    
 



 

                                                                       






http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381

http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928

http://stockcharts.com/freecharts/gallery.html?MSTX

                                                       

Contact Information

P: 858-552-0866    F: 858-552-0876
General Inquiries
info@mastthera.com

Investor Relations Contact
ir@mastthera.com

Business Development Contact
busdev@mastthera.com

Careers Contact
hr@mastthera.com

 

                                                                                                 

                                                                                                                                                 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSTX
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#12836   OT - while this board is hibernating, any RNsidersbuying 04/16/15 12:49:58 PM
#12835   It's election season - flip flopping is in RNsidersbuying 04/14/15 02:07:19 PM
#12834   Time to go for the $ imo, stop BooDog 04/14/15 01:34:08 PM
#12833   Been trying for .463 flippers and settled today RNsidersbuying 04/14/15 01:12:07 PM
#12832   I'm Bullish. I like the chart. Needs to BooDog 04/10/15 05:37:40 AM
#12831   this brushed the upper BB today. most okaly 04/09/15 10:13:21 PM
#12830   $MSTX Divergence showing signs of improvement. Needs BooDog 04/09/15 08:58:29 PM
#12829   wow this trades like a real POS okaly 04/09/15 04:11:23 PM
#12828   Mast To Present New Data Supporting Vepoloxamer (MST-188) BooDog 04/09/15 08:57:13 AM
#12827   http://www.cnbc.com/id/102572664 Rhodey Red 04/09/15 08:21:08 AM
#12826   Are we there yet? :-) Holding very nicely BooDog 04/08/15 02:23:13 PM
#12825   Okay, added in the .48's. Ready to BooDog 04/07/15 04:06:55 PM
#12824   lmao, I was just looking at that myself. BooDog 04/07/15 10:01:02 AM
#12823   Hear ya .... Only done it 3 or pray 04/07/15 12:26:46 AM
#12822   New Seeking Alpha article just released. http://seekingalpha.com/article/3051356 Rhodey Red 04/05/15 05:54:22 PM
#12821   I think so. See how the market BooDog 04/03/15 09:37:41 AM
#12820   Very close to flipper share buying again, no? RNsidersbuying 04/02/15 09:16:20 AM
#12819   Not sure if "bullish" is a good word pray 04/01/15 01:42:35 PM
#12818   Haha!!! Exactly Woulfe 03/30/15 11:46:19 AM
#12817   I opened the link hoping to see a pray 03/30/15 11:45:08 AM
#12816   Absolutely!!! Open market stock buys (code P) are Rhodey Red 03/30/15 09:22:50 AM
#12815   Thx Rhodey. Always good to know this. Cicant 03/30/15 09:18:22 AM
#12814   Good to see this... $TRIG$ 03/30/15 08:59:14 AM
#12813   Mast CFO insider stock Purchase!! http://insideri.com/1516354_000120919115030054 Rhodey Red 03/30/15 08:53:34 AM
#12812   Bx3 03/25/15 09:03:50 PM
#12811   I said something in my last post that Bx3 03/25/15 09:03:49 PM
#12810   I got a call yesterday around the time Bx3 03/25/15 08:10:53 PM
#12809   Is MSTX gonna break out if this range, JDLAXXE 03/25/15 12:23:20 AM
#12808   Today's New 10K is an invaluable read. I Rhodey Red 03/24/15 08:59:05 PM
#12807   Happy to have you back Hog!!!! That bodes Rhodey Red 03/24/15 11:30:10 AM
#12806   back in at 0.53...hog hogfan2 03/24/15 09:57:49 AM
#12805   thank you rhodey..always watching you guys...it would be hogfan2 03/24/15 09:12:08 AM
#12804   http://www.marketwatch.com/story/mast-therapeutics-reports-fourth-quarter-and-fu Rhodey Red 03/24/15 08:15:53 AM
#12803   http://seekingalpha.com/news/2387706-mast-therapeutics-beats-by-0_01 Rhodey Red 03/24/15 08:11:34 AM
#12802   Waters warm Hog....ready to take another dip...grab another Rhodey Red 03/23/15 05:10:03 PM
#12801   Looking good over here...hog hogfan2 03/23/15 03:22:52 PM
#12799   I still like MSTX. Always a buy in JDLAXXE 03/23/15 01:37:25 PM
#12798   No thanks. It's of no importance who puts Cicant 03/23/15 01:22:19 PM
#12797   Thankyou Cicant for that post/ link. I think Bx3 03/23/15 11:47:45 AM
#12796   No prob. Cicant 03/23/15 10:20:36 AM
#12795   upgrades continue. :-) Looking to break through some BooDog 03/23/15 09:27:26 AM
#12794   MSTX - STRONG BUY ! Bernardo75 03/23/15 09:00:16 AM
#12793   Thanks for the link Cicant....I was reading through Rhodey Red 03/23/15 08:16:55 AM
#12792   http://www.masttherapeutics.com/investors/news/?releaseid=2027689 Cicant 03/23/15 08:07:50 AM
#12791   Thank you Rhodey Red for that excellent Bx3 03/22/15 04:38:51 PM
#12790   Love your passion Bx3!!! Here is a nice Rhodey Red 03/22/15 11:58:16 AM
#12789   And why wouldn't it go down? A healthy Bx3 03/22/15 07:26:30 AM
#12788   Great posts, Rhodey Red. TY ipulator_man 03/21/15 09:47:12 PM
#12787   Patent Q? Citrati 03/21/15 04:36:41 PM
#12786   I share your excitement regarding Mast's pipeline. Regardless Rhodey Red 03/21/15 10:42:23 AM
PostSubject